Maria R Zocchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2405394/publications.pdf

Version: 2024-02-01

91712 76196 5,309 124 40 69 citations h-index g-index papers 126 126 126 6285 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Molecular Therapy - Oncolytics, 2022, 24, 26-42.	2.0	26
2	Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence. Cancers, 2022, 14, 259.	1.7	3
3	ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease. International Journal of Molecular Sciences, 2021, 22, 4969.	1.8	11
4	Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect. Haematologica, 2021, , .	1.7	9
5	Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. Cancers, 2021, 13, 3417.	1.7	14
6	Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer. Cancers, 2020, 12, 104.	1.7	24
7	Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy. Cancers, 2020, 12, 1886.	1.7	19
8	Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor. Frontiers in Immunology, 2020, 11, 1483.	2.2	3
9	Physical Characterization of Colorectal Cancer Spheroids and Evaluation of NK Cell Infiltration Through a Flow-Based Analysis. Frontiers in Immunology, 2020, 11, 564887.	2.2	20
10	Human Gut-Associated Natural Killer Cells in Health and Disease. Frontiers in Immunology, 2019, 10, 961.	2.2	101
11	Design and Synthesis of Ionic Liquidâ€Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPIâ€Coated Gold Nanoparticles. ChemMedChem, 2019, 14, 686-698.	1.6	2
12	Immunomodulatory Properties of Mesenchymal Stromal Cells: Still Unresolved "Yin and Yang― Current Stem Cell Research and Therapy, 2019, 14, 344-350.	0.6	39
13	Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. Oncolmmunology, 2018, 7, e1421889.	2.1	28
14	How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. Frontiers in Immunology, 2018, 9, 262.	2.2	91
15	Zoledronate Triggers VÎ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures. Frontiers in Immunology, 2018, 9, 998.	2.2	34
16	Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts. Frontiers in Immunology, 2018, 9, 1150.	2.2	24
17	Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes. ChemMedChem, 2018, 13, 2119-2131.	1.6	7
18	Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector $\hat{I}^3\hat{I}$ T cells with antitumor activity. Oncolmmunology, 2017, 6, e1278099.	2.1	62

#	Article	IF	CITATIONS
19	ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncolmmunology, 2016, 5, e1123367.	2.1	50
20	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. European Journal of Medicinal Chemistry, 2016, 111, 193-201.	2.6	40
21	Stress immunity in lymphomas: mesenchymal cells as a target of therapy. Frontiers in Bioscience - Landmark, 2014, 19, 281.	3.0	4
22	γδââ,¬â€°T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition a Implications for Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 575.	and 2.2	57
23	Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor VÂ 2 T lymphocytes in non-Hodgkin lymphomas. Haematologica, 2014, 99, 131-139.	1.7	27
24	Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells. Immunology Letters, 2014, 159, 55-72.	1.1	120
25	NK Cell Autoreactivity and Autoimmune Diseases. Frontiers in Immunology, 2014, 5, 27.	2.2	77
26	How to exploit stress-related immunity against Hodgkin's lymphoma. Oncolmmunology, 2013, 2, e27089.	2.1	8
27	Selective Role of Mevalonate Pathway in Regulating Perforin but Not FasL and TNFalpha Release in Human Natural Killer Cells. PLoS ONE, 2013, 8, e62932.	1.1	17
28	Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment. Oncolmmunology, 2012, 1, 214-216.	2.1	4
29	High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood, 2012, 119, 1479-1489.	0.6	97
30	Defective Expression and Function of the Leukocyte Associated Ig-like Receptor 1 in B Lymphocytes from Systemic Lupus Erythematosus Patients. PLoS ONE, 2012, 7, e31903.	1.1	36
31	Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica, 2011, 96, 16-23.	1.7	35
32	Editorial [Hot Topic: Targeting the Microenvironment in Hematological Malignancies: How to Condition both Stromal and Effector Cells to Overcome Cancer Spreading(Guest Editors: Maria) Tj ETQq0 0 0 rgB	T 10 verloc	:k40 Tf 50 2
33	Down regulation of human natural killer cell–mediated cytolysis induced by blood transfusion: role of transforming growth factorâ€î² ₁ , soluble Fas ligand, and soluble Class I human leukocyte antigen. Transfusion, 2011, 51, 1567-1573.	0.8	27
34	Differential survival of γÎ⊤ cells, αβ⊤ cells and NK cells upon engagement of NKG2D by NKG2DLâ€expressing leukemic cells. International Journal of Cancer, 2011, 129, 387-396.	2.3	11
35	Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors. Current Medicinal Chemistry, 2011, 18, 5196-5205.	1.2	5
36	Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia. PLoS ONE, 2011, 6, e18925.	1.1	17

#	Article	IF	CITATIONS
37	Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. British Journal of Haematology, 2010, 151, 252-264.	1.2	13
38	Gammadelta T Lymphocytes Producing IFNγ and IL-17 in Response to Candida Albicans or Mycobacterial Antigens: Possible Implications for Acute and Chronic Inflammation. Current Medicinal Chemistry, 2009, 16, 4743-4749.	1,2	24
39	Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia, 2009, 23, 641-648.	3.3	107
40	Vδ1 T lymphocytes producing IFN-γ and IL-17 are expanded in HIV-1–infected patients and respond to Candida albicans. Blood, 2009, 113, 6611-6618.	0.6	153
41	Imatinib Mesylate Treatment Increases Lymphoplasmocytoid Cells through SDF-1 and BMP4/7 Production in the Bone Marrow of Patients with Chronic Myelogenous Leukaemia: Relationship with Clinical/Haematological Response Blood, 2009, 114, 3263-3263.	0.6	0
42	Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL). Clinical and Experimental Immunology, 2008, 82, 108-113.	1.1	1
43	Characterization of EN4 monoclonal antibody: a reagent with CD31 specificity. Clinical and Experimental Immunology, 2008, 96, 170-176.	1.1	12
44	Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells. Human Immunology, 2008, 69, 755-759.	1.2	14
45	Lack of the leukocyte-associated lg-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia, 2008, 22, 980-988.	3.3	50
46	Evidence for Increased Bone Marrow Lymphoplasmocytoid Cells and SDF1 Secretion in imatinib Treated CML. Relationship with Clinical/hemathological Response. Blood, 2008, 112, 4256-4256.	0.6	0
47	Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases. Current Medicinal Chemistry, 2007, 14, 3166-3170.	1.2	19
48	Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica, 2007, 92, 881-888.	1.7	330
49	Expansion of VÎ1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16–binding proteins. Blood, 2007, 109, 2078-2085.	0.6	56
50	In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand. Leukemia, 2007, 21, 253-260.	3.3	19
51	Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self-aggression. Autoimmunity Reviews, 2007, 6, 295-299.	2.5	18
52	Migratory Pathways of $\hat{I}^3\hat{I}$ T Cells and Response to CXCR3 and CXCR4 Ligands. Annals of the New York Academy of Sciences, 2007, 1107, 68-78.	1.8	22
53	NKG2D and Natural Cytotoxicity Receptors Are Involved in Natural Killer Cell Interaction with Selfâ€Antigen Presenting Cells and Stromal Cells. Annals of the New York Academy of Sciences, 2007, 1109, 47-57.	1.8	25
54	Relationship between Clinical/Hematological Response and Increase of Plamacells in the Bone Marrow of Patients with Chronic Myelogenous Leukemia Imatinib Mesylate Treatment (631) Blood, 2007, 110, 4552-4552.	0.6	1

#	Article	IF	Citations
55	ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia, 2006, 20, 689-695.	3.3	66
56	Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 323-333.	1.0	49
57	HIV-1 Tat Triggers TGF- \hat{l}^2 Production and NK Cell Apoptosis that is Prevented by Pertussis Toxin B. Clinical and Developmental Immunology, 2006, 13, 369-372.	3.3	31
58	Antigen Presenting Cells and Stromal Cells Trigger Human Natural Killer Lymphocytes to Autoreactivity: Evidence for the Involvement of Natural Cytotoxicity Receptors (NCR) and NKG2D. Clinical and Developmental Immunology, 2006, 13, 325-336.	3.3	19
59	Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors. Blood, 2005, 106, 2399-2408.	0.6	34
60	Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmunity Reviews, 2005, 4, 532-536.	2.5	25
61	Regulation of γδT cell survival by soluble HLA-I: Involvement of CD8 and activating killer Ig-like receptors. European Journal of Immunology, 2005, 35, 2670-2678.	1.6	16
62	Tumor-Induced Apoptosis of Human IL-2-Activated NK Cells: Role of Natural Cytotoxicity Receptors. Journal of Immunology, 2005, 174, 2653-2660.	0.4	57
63	Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors. Journal of Immunology, 2005, 175, 6352-6360.	0.4	157
64	VÎ'1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid. Cancer Research, 2004, 64, 9172-9179.	0.4	166
65	PECAM-1, Apoptosis and CD34+Precursors. Leukemia and Lymphoma, 2004, 45, 2205-2213.	0.6	13
66	Migration of Vι and Vι2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1–infected patients: competition by HIV-1 Tat. Blood, 2004, 103, 2205-2213.	0.6	120
67	Evidence for Killing of Mesenchymal Stem Cells (MSC) by Autologous Natural Killer Lymphocytes Blood, 2004, 104, 1290-1290.	0.6	2
68	Role of gammadelta T lymphocytes in tumor defense. Frontiers in Bioscience - Landmark, 2004, 9, 2588.	3.0	37
69	IFN-γ production in human NK cells through the engagement of CD8 by soluble or surface HLA class I molecules. European Journal of Immunology, 2003, 33, 3049-3059.	1.6	25
70	Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. Aids, 2003, 17, 2291-2298.	1.0	52
71	Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+CD14+circulating precursors: evidence for PECAM-1 involvement through Akt/PKB activation. Blood, 2003, 101, 186-193.	0.6	49
72	Transendothelial Migratory Pathways of Vl´1+TCRlĴĴĆ+ and Vl´2+TCRlĴĴĆ+ T Lymphocytes from Healthy Donors and Multiple Sclerosis Patients: Involvement of Phosphatidylinositol 3 Kinase and Calcium Calmodulin-Dependent Kinase II. Journal of Immunology, 2002, 168, 6071-6077.	0.4	46

#	Article	IF	CITATIONS
73	Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood, 2002, 99, 1706-1714.	0.6	82
74	Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood, 2002, 100, 4098-4107.	0.6	97
75	NK Cell Activation by Dendritic Cells Is Dependent on LFA-1-Mediated Induction of Calcium-Calmodulin Kinase II: Inhibition by HIV-1 Tat C-Terminal Domain. Journal of Immunology, 2002, 168, 95-101.	0.4	80
76	Human $\hat{I}^3\hat{I}$ T cells: a nonredundant system in the immune-surveillance against cancer. Trends in Immunology, 2002, 23, 14-18.	2.9	144
77	Beta(3)-mediated engulfment of apoptotic tumor cells by dendritic cells is dependent on CAMKII: inhibition by HIV-1 Tat. Journal of Leukocyte Biology, 2002, 71, 531-7.	1.5	4
78	CD8+ T lymphocytes induce polarized exocytosis of secretory lysosomes by dendritic cells with release of interleukin- $1\hat{l}^2$ and cathepsin D. Blood, 2001, 98, 2152-2159.	0.6	66
79	NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. European Journal of Immunology, 2001, 31, 1656-1665.	1.6	115
80	Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells. European Journal of Immunology, 2001, 31, 3667-3675.	1.6	34
81	uPA/uPAR System Is Active in Immature Dendritic Cells Derived from CD14+CD34+ Precursors and Is Down-Regulated upon Maturation. Journal of Immunology, 2000, 164, 712-718.	0.4	31
82	Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Letters, 2000, 481, 245-248.	1.3	52
83	p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. European Journal of Immunology, 1998, 28, 2086-2091.	1.6	82
84	Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the $\hat{l}\pm 1$ integrin I-domain. European Journal of Immunology, 1998, 28, 2530-2536.	1.6	25
85	Functional Association of Platelet Endothelial Cell Adhesion Molecule-1 and Phosphoinositide 3-Kinase in Human Neutrophils. Journal of Biological Chemistry, 1998, 273, 27768-27771.	1.6	75
86	Involvement of Dihydropyridine-sensitive Calcium Channels in Human Dendritic Cell Function. Journal of Biological Chemistry, 1998, 273, 7205-7209.	1.6	67
87	NKRP1A molecule is involved in transendothelial migration of CD4+ human T lymphocytes. Immunology Letters, 1997, 57, 121-123.	1.1	25
88	The selective engulfment of apoptotic bodies by dendritic cells is mediated by the $\hat{l}\pm v\hat{l}^23$ integrin and requires intracellular and extracellular calcium. European Journal of Immunology, 1997, 27, 1893-1900.	1.6	236
89	Phenotypic and functional analysis of CD4+ NKRP1A+ human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration. European Journal of Immunology, 1997, 27, 2345-2350.	1.6	56
90	Expression and function of NKRP1A molecule on human monocytes and dendritic cells. European Journal of Immunology, 1997, 27, 2965-2970.	1.6	50

#	Article	IF	Citations
91	Drugâ€induced <i>in vitro</i> inhibition of neutrophilâ€endothelial cell adhesion. British Journal of Pharmacology, 1996, 118, 471-476.	2.7	28
92	A functional monoclonal antibody recognizing the human alpha 1â€integrin lâ€domain. Tissue Antigens, 1996, 48, 47-51.	1.0	27
93	CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. European Journal of Immunology, 1996, 26, 759-767.	1.6	78
94	CD31-triggered rearrangement of the actin cytoskeleton in human natural killer cells. European Journal of Immunology, 1996, 26, 817-824.	1.6	42
95	Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by the use of cholera or pertussis toxin. European Journal of Immunology, 1996, 26, 967-975.	1.6	21
96	Physical and functional association of CD45 and CD3-TCR complex on CD1+ human thymocytes. Evidence that the engagement of CD45 molecules can prevent CD1+ thymocytes from apoptosis. International Immunology, 1996, 8 , 1947-1953.	1.8	3
97	The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function. FEBS Letters, 1995, 374, 323-326.	1.3	69
98	Expression of N-CAM by Human Renal Cell Carcinomas Correlates with Growth Rate and Adhesive Properties. Experimental Cell Research, 1994, 214, 499-509.	1.2	11
99	Inducible Nitric Oxide Synthase Modulates Fibronectin Production in the EA.hy926 Cell Line and Cultured Human Umbilical Vein Endothelial Cells. Journal of Cardiovascular Pharmacology, 1994, 24, 1014-1019.	0.8	14
100	NCAM and lymphocyte adhesion in leucocyte adhesion deficiency (LAD) syndrome. Trends in Immunology, 1993, 14, 94-95.	7.5	3
101	Involvement of CD56/N-CAM Molecule in the Adhesion of Human Solid Tumor Cell Lines to Endothelial Cells. Experimental Cell Research, 1993, 204, 130-135.	1.2	29
102	Lymphocyte-Endothelial Cell Adhesion Molecules at the Primary Tumor Site in Human Lung and Renal Cell Carcinomas. Journal of the National Cancer Institute, 1993, 85, 246-247.	3.0	31
103	Signalling in human tumour infiltrating lymphocytes: The CD28 molecule is functional and is physically associated with the CD45R0 molecule. European Journal of Cancer, 1992, 28, 749-754.	1.3	11
104	5.7 Cell cycle related expression of early activation antigens in human thymocytes. Progress in Histochemistry and Cytochemistry, 1992, 26, 223-228.	5.1	0
105	Cultured human thymocytes lacking CD2 and CD11a/CD18 antigens are functional and adhere to endothelial cells via CD56 or CDw49d molecules. Cellular Immunology, 1992, 140, 319-330.	1.4	7
106	Antigen-independent pathways of T-cell activation are functional in human immature thymocytes. International Journal of Clinical and Laboratory Research, 1992, 21, 304-309.	1.0	0
107	Unusual expression and localization of heat-shock proteins in human tumor cells. International Journal of Cancer, 1992, 51, 613-619.	2.3	417
108	Activation of CD3/TCR negative human thymocytes via CD28 molecule. Cellular Immunology, 1991, 136, 105-112.	1.4	2

#	Article	IF	Citations
109	Biochemical characterization by two-dimensional electrophoresis of lymphocyte antigens involved in cell-to-cell or cell-to-matrix adhesion. Electrophoresis, 1991, 12, 527-535.	1.3	3
110	LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes. British Journal of Cancer, 1990, 62, 754-757.	2.9	3
111	CD1+ thymocytes proliferate and give rise to functional cells after stimulation with monoclonal antibodies recognizing CD3, CD2 or CD28 surface molecules. Cellular Immunology, 1990, 129, 394-403.	1.4	7
112	Simultaneous cytofluorometric analysis for the expression of cytoplasmic antigens and DNA content in CD3â^' human thymocytes. Cytometry, 1990, 11, 883-887.	1.8	8
113	Identification of a new surface molecule expressed by human LGL and LAK cells: Production of a specific monoclonal antibody and comparison with other NK/LAK markers. Cellular Immunology, 1989, 124, 144-157.	1.4	13
114	Ck226: a novel surface molecule involved in human t cell activation. European Journal of Immunology, 1989, 19, 2069-2074.	1.6	5
115	Dual-parameter flow cytometric analysis of an early lymphocyte activation antigen (CK226) and DNA content. Cytometry, 1989, 10, 762-771.	1.8	3
116	Human cytolytic cell clones lacking surface expression of T cell receptor alpha/beta or gamma/delta. Evidence that surface structures other than CD3 or CD2 molecules are required for signal transduction Journal of Experimental Medicine, 1988, 168, 13-24.	4.2	41
117	A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function Journal of Experimental Medicine, 1987, 166, 319-326.	4.2	29
118	Production of Monoclonal Antibodies Specific to Theophylline-Treated Lymphocytes. Hybridoma, 1987, 6, 403-411.	0.9	1
119	CD3+ WT31â^' peripheral T lymphocytes lack T44 (CD28), a surface molecule involved in activation of T cells bearing the $\hat{l}\pm/\hat{l}^2$ heterodimer. European Journal of Immunology, 1987, 17, 1065-1068.	1.6	52
120	Adenosine induced production of a soluble factor affecting lymphocyte activation. Immunology Letters, 1986, 13, 245-253.	1.1	1
121	Theoylline Induced Non Specific Suppressor Activity in Human Peripheral Blood Lymphocytes. Immunopharmacology and Immunotoxicology, 1985, 7, 217-234.	0.8	16
122	Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma. Clinical and Experimental Allergy, 1984, 14, 443-452.	1.4	8
123	Effect of Corticoids on Neutrophil Function: Inhibition of Antibody-Dependent Cell, Mediated Cytotoxicity (ADCC). Immunopharmacology and Immunotoxicology, 1983, 5, 217-230.	0.8	9
124	Anti-cancer $\hat{l}^3\hat{l}^*T$ lymphocytes: contradictory past and promising future. Exploration of Immunology, 0, , 220-228.	1.7	0